VIDEO: EyePoint shares updates on Duravyu for wet AMD, DME

CHICAGO — In this Healio Video Perspective from the AAO meeting, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, shares an update on Duravyu for wet age-related macular degeneration.

Duker discussed positive phase 2 data from the DAVIO 2 trial investigating Duravyu, an intravitreal insert that delivers vorolanib, a tyrosine kinase inhibitor, and previews two upcoming pivotal trials comparing Duravyu with Eylea (aflibercept 2 mg, Regeneron) for the treatment of wet AMD.

“In addition, we have a phase 2 trial called the VERONA trial in diabetic macular edema that is due to read out in the first quarter of 2025,” he said.

Published by:

Read more about

This post was originally published on this site